Patents Assigned to Genentech
  • ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF
    Publication number: 20180021450
    Abstract: The invention provides anti-Staphylococcus aureus antibody rifamycin antibiotic conjugates and methods of using same.
    Type: Application
    Filed: June 2, 2017
    Publication date: January 25, 2018
    Applicant: Genentech, Inc.
    Inventors: Eric Brown, Wouter Hazenbos, Isidro Hotzel, Kimberly Kajihara, Sophie M. Lehar, Sanjeev Mariathasan, Thomas Pillow, Leanna Staben, Vishal Verma, Binqing Wei, Min Xu
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20180022727
    Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: July 7, 2017
    Publication date: January 25, 2018
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Victor Gehling, Vickie Hsiao-Wei Tsui, James Richard Jr. Kiefer, Jun Liang, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Birong Zhang
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
    Publication number: 20180021431
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 25, 2018
    Applicant: Genentech, Inc.
    Inventors: Heather MAECKER, Bryan IRVING
  • ANTIGEN BINDING COMPLEX HAVING AGONISTIC ACTIVITY AND METHODS OF USE
    Publication number: 20180022813
    Abstract: Provided herein are antigen binding polypeptides and complexes thereof having agonist activity. Also provided are methods for screening for complexes or polypeptides having agonist activity, enhancing the agonist activity of a polypeptide, and for agonizing a cell surface receptor using the complexes and polypeptide described herein.
    Type: Application
    Filed: October 4, 2017
    Publication date: January 25, 2018
    Applicant: Genentech, Inc.
    Inventors: Greg LAZAR, Jeong KIM, Jing ZHU, Yanli YANG, Randall BREZSKI
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20180022707
    Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: July 7, 2017
    Publication date: January 25, 2018
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Victor Gehling, Vickie Hsiao-Wei Tsui, James Richard Jr. Kiefer, Jun Liang, Steven Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Alexander M. Taylor
  • Bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1
    Patent number: 9873748
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: January 23, 2018
    Assignee: GENENTECH, INC.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
    Patent number: 9873740
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: January 23, 2018
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Triazolopyridine compounds, compositions and methods of use thereof
    Patent number: 9873709
    Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: January 23, 2018
    Assignee: Genentech, Inc.
    Inventors: Nicholas C. Ray, Yun-Xing Cheng, Christine Edwards, Simon C. Goodacre, Wei Li, Snahel Patel, Matthew W. Cartwright, Mohammed Sajad, Po-wai Yuen, Mark E. Zak
  • Estrogen receptor modulators and uses thereof
    Patent number: 9873684
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: January 23, 2018
    Assignee: Genentech, Inc.
    Inventors: Mehmet Kahraman, Steven P. Govek, Nicholas D. Smith, Jeffrey H. Hager, Edna Chow Maneval
  • Methods for diagnosing and treating inflammatory bowel disease
    Patent number: 9873742
    Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: January 23, 2018
    Assignee: Genentech, Inc.
    Inventors: Mary Keir, Gaik Wei Tew
  • Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
    Patent number: 9873734
    Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: January 23, 2018
    Assignee: GENENTECH, INC.
    Inventors: Sek Chung Fung, Kang Li, Zhengbin Yao
  • ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES
    Publication number: 20180016325
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20180015177
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 27, 2017
    Publication date: January 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Peter Chang, Chie Sakanaka
  • ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20180015179
    Abstract: The invention provides anti-CD79b antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 26, 2017
    Publication date: January 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Paul Polakis, Andrew G. Polson, Susan Diane Spencer, Shang-Fan Yu, Bing Zheng
  • Protein purification
    Patent number: 9868760
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: January 16, 2018
    Assignee: GENENTECH, INC.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • C-linked heterocycloaklyl substituted pyrimidines and their uses
    Patent number: 9868720
    Abstract: The present invention provides for pyrimidine compounds of Formula I-I and embodiments thereof In Formula I-I in which R1, R2, R3, R4, R5, R6, m, n and the “het” ring are as described herein. Also provided are pharmaceutical compositions comprising compounds of Formula I and methods of using such compounds and compositions.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: January 16, 2018
    Assignee: Genentech, Inc.
    Inventors: Frederick Cohen, Snahel Patel
  • Serine/threonine kinase inhibitors
    Patent number: 9867833
    Abstract: Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: January 16, 2018
    Assignee: GENENTECH, INC.
    Inventors: Aleksandr Kolesnikov, Steven Do
  • Estrogen receptor modulators and uses thereof
    Patent number: 9868704
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 16, 2018
    Assignee: Genentech, Inc.
    Inventors: Nicholas D. Smith, Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Andiliy G. Lai, Jackaline D. Julien, Mark R. Herbert, Karensa L. Douglas
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20180009805
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.
    Type: Application
    Filed: July 24, 2017
    Publication date: January 11, 2018
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Daniel J. Burdick, Terry Crawford, Martin Duplessis, Steven R. Magnuson, Christopher G. Nasveschuk, Anthony F. Romero, Yong Tang, Vickie Hsiao-Wei Tsui, Shumei Wang
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20180009735
    Abstract: Provided herein are compounds of formula I: and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.
    Type: Application
    Filed: July 24, 2017
    Publication date: January 11, 2018
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Cote, Martin Duplessis, Victor S. Gehling, Andrew Charles Good, Jean-Christophe Harmange, Yves LeBlanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani